The Evolving Role of ADCs in NSCLC: A Focus on TROP2-Directed Therapies

home / precision-medicine / the-evolving-role-of-adcs-in-nsclc-a-focus-on-trop2-directed-therapies

Anne S.Tsao, MD, and Edward B. Garon, MD, MS, review clinical trial data and discuss the evolving role of antibody-drug conjugates and TROP2-directed therapies in the treatment of patients with non–small cell lung cancer.

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 1: Overview of Non–Small Cell Lung Cancer

Anne S. Tsao, MD;Edward B. Garon, MD, MS
November 16th 2023

Anne S. Tsao, MD, and Edward B. Garon, MD, MS, introduce themselves and provide an overview of the incidence, prognosis, and treatment of non–small cell lung cancer.

Watch

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 2: The Role of Biomarkers in NSCLC Treatment

Anne S. Tsao, MD;Edward B. Garon, MD, MS
November 16th 2023

Thoracic medical oncologists discuss the evolving role of biomarkers in the non–small cell lung cancer treatment landscape.

Watch

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 3: NSCLC Treatment: Unmet Needs and Antibody-Drug Conjugates

Anne S. Tsao, MD;Edward B. Garon, MD, MS
November 23rd 2023

Expert perspectives on unmet needs in the NSCLC treatment landscape and the role of antibody-drug conjugates in addressing them.

Watch

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 4: The Role of TROP2 as a Biomarker in NSCLC

Anne S. Tsao, MD;Edward B. Garon, MD, MS
November 23rd 2023

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, provide an overview of TROP2 as a target for patients with non–small cell lung cancer.

Watch

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 5: NSCLC: Preclinical Studies on TROP2 Expression

Anne S. Tsao, MD;Edward B. Garon, MD, MS
November 30th 2023

A review of preclinical studies looking at TROP2 expression in patients with non–small cell lung cancer.

Watch

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 6: Lung Cancer Treatment: Antibody-Drug Conjugates

Anne S. Tsao, MD;Edward B. Garon, MD, MS
November 30th 2023

Experts on non–small cell lung cancer discuss the role of antibody-drug conjugates and review their mechanism of action.

Watch

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 7: Clinical Trial Data on Sacituzumab Govitecan in NSCLC

Anne S. Tsao, MD;Edward B. Garon, MD, MS
December 7th 2023

Comprehensive insights on clinical trial data that have led to further development of sacituzumab govitecan for patients with non–small cell lung cancer.

Watch

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 8: EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in First-Line Metastatic NSCLC

Anne S. Tsao, MD;Edward B. Garon, MD, MS
December 7th 2023

Thoracic oncologists discuss the EVOKE-02 study investigating sacituzumab govitecan in combination with pembrolizumab in patients with first-line metastatic NSCLC.

Watch

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 9: Advanced NSCLC: TROPION-Lung02 and TROPION-Lung04

Anne S. Tsao, MD;Edward B. Garon, MD, MS
December 15th 2023

A brief overview of clinical trials investigating datopotamab deruxtecan in patients with non–small cell lung cancer.

Watch

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 10: Antibody-Drug Conjugate Safety Profiles in NSCLC

Anne S. Tsao, MD;Edward B. Garon, MD, MS
December 15th 2023

Edward B. Garon, MD, MS, reviews the safety profiles of sacituzumab govitecan and datopotamab deruxtecan in patients with non–small cell lung cancer.

Watch

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 11: Recent Data on Datopotamab Deruxtecan in NSCLC

Anne S. Tsao, MD;Edward B. Garon, MD, MS
December 21st 2023

An overview of clinical trials investigating datopotamab derutecan in patients with non–small cell lung cancer.

Watch

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 12: NSCLC: Dato-DXd Combination Therapy

Anne S. Tsao, MD;Edward B. Garon, MD, MS
December 21st 2023

Expert perspectives on clinical trials investigating doublet and triplet therapy with datopotamab deruxtecan in patients with non–small cell lung cancer.

Watch

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 13: NSCLC: Role of ADCs and Ongoing EVOKE-01 and EVOKE-03 Studies

Anne S. Tsao, MD;Edward B. Garon, MD, MS
December 28th 2023

Medical oncologists discuss where antibody-drug conjugates fit in the overall non–small cell lung cancer treatment landscape and review the ongoing EVOKE-01 and EVOKE-03 clinical trials.

Watch

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 14: Progress and Unmet Needs in NSCLC Treatment

Anne S. Tsao, MD;Edward B. Garon, MD, MS
December 28th 2023

Thoracic oncologists discuss the progress made and unmet needs that remain in the non–small cell lung cancer treatment space.

Watch

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 15: Future Targeted Therapy Approaches in NSCLC

Anne S. Tsao, MD;Edward B. Garon, MD, MS
January 4th 2024

Anne S. Tsao, MD, and Edward B. Garon, MD, MS, conclude their discussion with a look to the future of TROP2 and associated targeted therapy approaches in non–small cell lung cancer.

Watch